Lancashire and South Cumbria
Formulary
Formulary
4 Central nervous system
This chapter of the formulary is under continual development, please let the team know if you have any comments about the contents: mlcsu.lscformulary@nhs.net.
For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
04-09-01 Monoamine-oxidase-B inhibitors
| Selegiline Hydrochloride Zelapar® |
|
Second Choice
|
Oral lyophilisate 1.25mg |
|
| Rasagiline Azilect® |
|
Second Choice
|
Tablets 1mg |
|
|
Links
BNF: Parkinson’s disease- How do you convert from co-beneldopa (Madopar®) prolonged-release capsules to dispersible tablets?
LSCMMG: Shared care guideline- LSCMMG: The Management of Restless Legs Syndrome in Adults in Primary Care
- MHRA Drug Safety Update April 2016: Apomorphine with domperidone: minimising risk of cardiac side effects
- MHRA: Apomorphine with domperidone: minimising risk of cardiac side effects
- NICE NG71: Parkinson’s disease in adults
- NICE TA934: Foslevodopa–foscarbidopa for treating advanced Parkinson’s with motor symptoms
- NICE TA934:Foslevodopa–foscarbidopa for treating advanced Parkinson’s with motor symptoms
- Shared Care Guideline - Apomorphine